This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
IntroductionThe objective of this study was to examine the impact of ventricular assist device support as a bridge to hearttransplantation in children with end-stage heartfailure. Patients were divided into two groups: with pre transplant ventricular assist device (VAD) support and without VAD support.
RELIEVE-HF investigators evaluated the efficacy and safety of the V-wave interatrial shunt system in patients with heartfailure. The primary endpoint was a composite of all-cause mortality, left ventricular assist device (LVAD)/hearttransplantation, HF hospitalizations, worsening HF, and KCCQ score changes. Atlanta, GA.
Background Belt electrode skeletal muscle electrical stimulation (B-SES) is an emerging therapy anticipated to yield more favorable outcomes than conventional neuromuscular electrical stimulation (NMES), owing to its larger stimulation area. However, information on its efficacy and safety in patients with heartfailure remains limited.
THE TEXAS HEART INSTITUTE 2024 milla1cf Tue, 02/13/2024 - 17:56 February 13, 2024 — Pediatric hearttransplantation has long been hailed as a life-saving intervention for children suffering from end-stage heartfailure. The research is a collaborative effort between leading medical institutions.
Pediatric hearttransplantation has long been hailed as a life-saving intervention for children suffering from end-stage heartfailure. While the procedure offers hope, the long-term outcomes for these young patients remain suboptimal due to allograft rejection and graft failure.
After struggling with heartfailure for the first months of his life, doctors told his parents that Zeke would need a hearttransplant immediately. Within one day, our hearttransplant team performed the transplant surgery. Now Zane, 6, and Zeke, 5, are living lives the odds said were unlikely.
As the only pediatric hearttransplant program in Louisiana and the only program in the state to offer advanced mechanical support options for pediatric cardiology patients, Ochsner Children’s Hospital is committed to advocating for additional medical devices to enhance its high-quality care to pediatric patients awaiting transplant.
Kittleson, director of HeartFailure Research and director of Post Graduate Medical Education in HeartFailure and Transplantation, is an associate editor specializing in heartfailure. Levine Early Career Clinical Investigator Award from the American Heart Association.
Ashley Malliett, DMSc, MPAS, PA-C, discusses the importance of timely diagnosis and initiated care, as well as contraindications for transplants and LVAD.
The implantation of left ventricular assist devices (LVADs) has been increasing, with good long-term results, in parallel with a growing population with advanced heartfailure (HF). However, in some European countries, LVADs are still underused, with one of the main issues being the patient's late referral.
Objective The role of hyperuricaemia as a prognostic maker has been established in chronic heartfailure (HF) but limited information on the association between plasma uric acid (UA) levels and central haemodynamic measurements is available. UA) was used to estimate the effect on outcome associated with a 10% increase in UA levels.
Circulation: HeartFailure, Ahead of Print. Heartfailure is a global disease with significant morbidity. Hearttransplant (HT) can be a lifesaving therapy for select patients with end-stage heartfailure.
Arrhythmias can lead to cardiac arrest (CA) and heartfailure. When intractable, hearttransplant (HTX) can become the only viable treatment. This rare, high-risk cohort has not been reported as a distinct group.
Hearttransplant rates were low but increased slightly in 2020 for patients without CHD, with DV and SV CHD patients showing fluctuating rates peaking in 2018 and 2019, then declining in 2020. Patients without CHD were older (mean age 71.5 years) than those with DV-CHD (mean age 59.8 years) and SV-CHD (mean age 17.9
Circulation: HeartFailure, Ahead of Print. Centers performing at least 1 hearttransplant or left ventricular assist device were classified as ATCs. Patient characteristics, outcomes, and procedural volume were compared among 3 cohorts: admissions to non-ATCs, admissions to ATCs, and transfers to ATCs.
Knowledge and application of European Society of Cardiology/HeartFailure Association (ESC/HFA) guidelines in the management of advanced heartfailure (HF). Respondents were categorized into heartfailure cardiologists (HFCs), general cardiologists (GCs), and other participants (OPs). of HFCs, 19.6%
Venn diagram of iron deficiency (ID) according to various definitions and associated outcomes. Abstract Aims There is uncertainty about the definition of iron deficiency (ID) and the association between ID and prognosis in patients with advanced heartfailure. Non-scaled VENN diagram.
Hearttransplantation remains a vital treatment for end-stage heartfailure, yet the scarcity of suitable donor hearts makes the treatment unavailable to many patients in critical need. Addressing this critical barrier could potentially improve post-transplantoutcomes and make older donor hearts a viable option.
Hematopoietic stem cell transplantation can cure various disorders but poses cardiovascular risks, especially for elderly patients and those with cardiovascular diseases. Acute heartfailure has an incidence ranging from 0.4% Cardiovascular evaluations are crucial in pretransplantation assessments, but guidelines are lacking.
Abstract Aims The CASTLE-HTx trial showed the benefit of atrial fibrillation (AF) ablation compared to medical therapy in decreasing mortality, need for left ventricular assist device implantation or hearttransplantation (HTx) in patients with end-stage heartfailure (HF).
Introduction:Pediatric hearttransplant (PHT) recipient survival has improved. Yet, neurologic morbidity related to heartfailure and its treatment persist. It can affect the functional outcome, increase risk of major adverse events, prolong LOS and increase the use of rehabilitation therapies (RT).
Abstract Aim Cardiac resynchronization therapy (CRT) is a cornerstone in the management of chronic heartfailure in patients with a broad or paced QRS. However, data on long-term outcome after upgrade to CRT are scarce. The secondary endpoint was first heartfailure admission. ml/min/1.73 m ml/min/1.73 m
The associations between PPM implantation and mortality, heartfailure (HF) or a composite endpoint of mortality, cardiac transplantation and HF were analysed. Clinical, laboratory and instrumental data were analysed. Results 81 (10.3%) patients had a PPM before initial evaluation. Over a median follow-up time of 21.7
Circulation: HeartFailure, Ahead of Print. BACKGROUND:Right ventricular dysfunction (RVD) is common in patients with heartfailure with reduced ejection fraction, and it is associated with poor prognosis. Plasma levels of FMOD and FBLN5 were significantly associated with patient outcomes (P=0.005;P=0.004).
We collected demographic, pre-procedural, procedural, and outcome-related variables. The association between a lower rate of MAE and EMB persisted in the multivariate model when those with hearttransplant who had EMB were compared to those without hearttransplant who did not have EMB p=0.001. were females.
BACKGROUND:A growing number of patients with tetralogy of Fallot develop left ventricular systolic dysfunction and heartfailure, in addition to right ventricular dysfunction. Outcomes were analyzed at early (3 months), intermediate (1 year), and late follow-up (≥2 years) after CRT implantation.RESULTS:A total of 44 patients (40.3±19.2
Background:Cardiac transplantation remains the single most effective treatment for end-stage heartfailure. Despite the routine use of anti-rejection drugs in clinical practice, approximately 40% of cardiac transplant patients still experience unavoidable rejection. at POD 7 days; P<0.001).
Key findings presented at the conference included disparities in access to kidney transplantation and waitlisting based on race and neighborhood characteristics, racial and ethnic differences in incident chronic kidney disease (CKD), and the use of motivational strategies to improve dialysis nonadherence among African American patients.
Venoarterial extracorporeal membrane oxygenation (VA-ECMO) use to provide hemodynamic support for acute myocardial infarction has grown exponentially, is associated with poor outcomes, and is under active clinical investigation, yet the mechanistic effect of VA-ECMO on myocardial damage in acute myocardial infarction remains poorly understood.
The Resynchronization–Defibrillation for Ambulatory HeartFailure Trial (RAFT; NCT00251251 ) demonstrated a greater 5-year mortality benefit for patients receiving cardiac-resynchronization therapy (CRT) compared to those receiving implantable cardioverter–defibrillators (ICDs). Secondary outcomes were experienced by 77.7%
The trial, called RELIEVE-HF , is the first randomized placebo-procedure controlled trial of interatrial shunting that included patients with both major types of heartfailure : heartfailure with reduced ejection fraction (HFrEF) and heartfailure with preserved ejection fraction (HFpEF).
CMS has reviewed the CardiAMP HeartFailure II Trial and approved the investigational product, related and routine items and services for purposes of Medicare coverage. The CardiAMP HeartFailure II Trial is FDA approved to enroll up to 250 patients at up to 40 clinical centers. said Peter Altman , PhD.,
The trial, called RELIEVE-HF , is the first randomized placebo-procedure controlled trial of interatrial shunting that included patients with both major types of heartfailure : heartfailure with reduced ejection fraction (HFrEF) and heartfailure with preserved ejection fraction (HFpEF).
a privately held company dedicated to advancing the treatment of heartfailure ( HF ) at the intersection of digital health and medtech, today announced Premarket Approval (PMA) from the U.S milla1cf Mon, 06/24/2024 - 20:21 June 24, 2024 — Endotronix, Inc. ,
Background Objective tools to define the optimal time for referral for advanced therapies and to help guide escalation and de-escalation of support can improve management decisions and outcomes for patients with advanced heartfailure. Results Approximately 1010 discrete heartfailure scenarios were modeled.
The DRAIN-HF study will evaluate the Aortix percutaneous mechanical circulatory support (pMCS) technology in patients with acute decompensated heartfailure (ADHF) who are unresponsive to standard medical therapy. I am excited to be able to include the advanced heartfailure patients in the trial," commented Dr. Grafton.
The primary outcome was all-cause death and hearttransplantation. Secondary heartfailure (HF) and arrhythmic outcomes were also included. A total of 492 first degree relatives were enrolled. However, LV systolic dysfunction detected by FSP showed a better prognosis.
These methods only alleviate symptoms of heartfailure and myocardial ischemia and improve patients' quality of life by partially restoring myocardial reperfusion. It has become an urgent task for clinical medicine to seek new and better treatment.
Study shows that cardiac spheroids, derived from human induced pluripotent stem cells, can be easily transported and injected into damaged areas of the heart to promote its regeneration and recovery of function. The highly positive outcomes observed in primate models highlight the potential of this strategy.
Characteristics of heartfailure with improved ejection fraction (HFimpEF) patients and outcome comparison with heartfailure with persistently reduced ejection fraction (pHFrEF). CV mortality is the composite endpoint for CV mortality + urgent transplant + left ventricular assist device implantation.
Circulation: HeartFailure, Ahead of Print. BACKGROUND:In 2018, an algorithm-based allocation system for hearttransplantation (HT) was implemented in France. The cumulative incidence of waitlist mortality estimated with competing risk analysis and incidence of transplantation were compared between diagnosis groups.
Background and aimDilated cardiomyopathy (DCM) is the most common heart muscle disease presenting in childhood and is associated with an increased risk of heartfailure related death. All but one study was retrospective and only one had a patient cohort of more than 100 patients.
Aims Timely referrals for transplantation and left ventricular assist device (LVAD) play a key role in favourable outcomes in patients with advanced heartfailure (HF). Cardiovascular mortality, driven by sudden cardiac death, is the main reason for dying while waiting for hearttransplantation (HTx).
BACKGROUND:In hearttransplant recipients, right ventricular (RV) dysfunction may occur for a variety of reasons. Whether RV dysfunction in the stable phase after hearttransplantation is associated with long-term adverse outcomes is unknown. years after hearttransplantation were included.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
52 
Let's personalize your content